Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer

Keiichiro Nakamura, Norio Takamoto, Atsushi Hongo, Junichi Kodama, Fernando Abrzua, Yasutomo Nasu, Hiromi Kumon, Yuji Hiramatsu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In light of the poor prognosis for ovarian cancer, research continues for innovative and efficacious treatment modalities. It is now widely accepted that new approaches for the treatment of ovarian cancers are pivotal in further improving prognosis of this disease. Secretory leukoprotease inhibitor (SLPI) is an 11.7-kDa non-glycosylated, serine protease inhibitor that has a broad inhibitory spectrum against serine protease. SLPI showed potential therapeutic inhibitory effects mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TNF-α, death receptor (DR)-4, DR-5 and TNF receptor (TNFR)-I expression which lead to an activation of apoptosis pathway through Caspase-2, Caspase-8 and Caspase-9. We examined whether levels of SLPI protein expression correlated with clinico-pathological characteristics in 58 ovarian cancer samples, and investigated the role of SLPI and its biological functions. SLPI expression showed a significant correlation between low expression of SLPI and amount of ascites (p=0.021), lymph node metastasis (p=0.011). We propose that SLPI could be considered a therapeutic target for the treatment of ovarian cancer.

Original languageEnglish
Pages (from-to)1085-1091
Number of pages7
JournalOncology Reports
Volume19
Issue number5
Publication statusPublished - May 2008

Fingerprint

Secretory Leukocyte Peptidase Inhibitor
Ovarian Neoplasms
Growth
TNF-Related Apoptosis-Inducing Ligand Receptors
Tumor Necrosis Factor Receptors
Caspase 2
Apoptosis
Serine Proteinase Inhibitors
Caspase 9
Caspase 8
Serine Proteases
Therapeutic Uses
Ascites
Tumor Necrosis Factor-alpha
Lymph Nodes
Neoplasm Metastasis
Ligands

Keywords

  • Apoptotic pathway
  • Caspase
  • Ovarian cancer
  • Secretory leukoprotease inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nakamura, K., Takamoto, N., Hongo, A., Kodama, J., Abrzua, F., Nasu, Y., ... Hiramatsu, Y. (2008). Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer. Oncology Reports, 19(5), 1085-1091.

Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer. / Nakamura, Keiichiro; Takamoto, Norio; Hongo, Atsushi; Kodama, Junichi; Abrzua, Fernando; Nasu, Yasutomo; Kumon, Hiromi; Hiramatsu, Yuji.

In: Oncology Reports, Vol. 19, No. 5, 05.2008, p. 1085-1091.

Research output: Contribution to journalArticle

Nakamura, K, Takamoto, N, Hongo, A, Kodama, J, Abrzua, F, Nasu, Y, Kumon, H & Hiramatsu, Y 2008, 'Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer', Oncology Reports, vol. 19, no. 5, pp. 1085-1091.
Nakamura, Keiichiro ; Takamoto, Norio ; Hongo, Atsushi ; Kodama, Junichi ; Abrzua, Fernando ; Nasu, Yasutomo ; Kumon, Hiromi ; Hiramatsu, Yuji. / Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer. In: Oncology Reports. 2008 ; Vol. 19, No. 5. pp. 1085-1091.
@article{60fb83c550ad4244bc42d5765f9da463,
title = "Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer",
abstract = "In light of the poor prognosis for ovarian cancer, research continues for innovative and efficacious treatment modalities. It is now widely accepted that new approaches for the treatment of ovarian cancers are pivotal in further improving prognosis of this disease. Secretory leukoprotease inhibitor (SLPI) is an 11.7-kDa non-glycosylated, serine protease inhibitor that has a broad inhibitory spectrum against serine protease. SLPI showed potential therapeutic inhibitory effects mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TNF-α, death receptor (DR)-4, DR-5 and TNF receptor (TNFR)-I expression which lead to an activation of apoptosis pathway through Caspase-2, Caspase-8 and Caspase-9. We examined whether levels of SLPI protein expression correlated with clinico-pathological characteristics in 58 ovarian cancer samples, and investigated the role of SLPI and its biological functions. SLPI expression showed a significant correlation between low expression of SLPI and amount of ascites (p=0.021), lymph node metastasis (p=0.011). We propose that SLPI could be considered a therapeutic target for the treatment of ovarian cancer.",
keywords = "Apoptotic pathway, Caspase, Ovarian cancer, Secretory leukoprotease inhibitor",
author = "Keiichiro Nakamura and Norio Takamoto and Atsushi Hongo and Junichi Kodama and Fernando Abrzua and Yasutomo Nasu and Hiromi Kumon and Yuji Hiramatsu",
year = "2008",
month = "5",
language = "English",
volume = "19",
pages = "1085--1091",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer

AU - Nakamura, Keiichiro

AU - Takamoto, Norio

AU - Hongo, Atsushi

AU - Kodama, Junichi

AU - Abrzua, Fernando

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

AU - Hiramatsu, Yuji

PY - 2008/5

Y1 - 2008/5

N2 - In light of the poor prognosis for ovarian cancer, research continues for innovative and efficacious treatment modalities. It is now widely accepted that new approaches for the treatment of ovarian cancers are pivotal in further improving prognosis of this disease. Secretory leukoprotease inhibitor (SLPI) is an 11.7-kDa non-glycosylated, serine protease inhibitor that has a broad inhibitory spectrum against serine protease. SLPI showed potential therapeutic inhibitory effects mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TNF-α, death receptor (DR)-4, DR-5 and TNF receptor (TNFR)-I expression which lead to an activation of apoptosis pathway through Caspase-2, Caspase-8 and Caspase-9. We examined whether levels of SLPI protein expression correlated with clinico-pathological characteristics in 58 ovarian cancer samples, and investigated the role of SLPI and its biological functions. SLPI expression showed a significant correlation between low expression of SLPI and amount of ascites (p=0.021), lymph node metastasis (p=0.011). We propose that SLPI could be considered a therapeutic target for the treatment of ovarian cancer.

AB - In light of the poor prognosis for ovarian cancer, research continues for innovative and efficacious treatment modalities. It is now widely accepted that new approaches for the treatment of ovarian cancers are pivotal in further improving prognosis of this disease. Secretory leukoprotease inhibitor (SLPI) is an 11.7-kDa non-glycosylated, serine protease inhibitor that has a broad inhibitory spectrum against serine protease. SLPI showed potential therapeutic inhibitory effects mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TNF-α, death receptor (DR)-4, DR-5 and TNF receptor (TNFR)-I expression which lead to an activation of apoptosis pathway through Caspase-2, Caspase-8 and Caspase-9. We examined whether levels of SLPI protein expression correlated with clinico-pathological characteristics in 58 ovarian cancer samples, and investigated the role of SLPI and its biological functions. SLPI expression showed a significant correlation between low expression of SLPI and amount of ascites (p=0.021), lymph node metastasis (p=0.011). We propose that SLPI could be considered a therapeutic target for the treatment of ovarian cancer.

KW - Apoptotic pathway

KW - Caspase

KW - Ovarian cancer

KW - Secretory leukoprotease inhibitor

UR - http://www.scopus.com/inward/record.url?scp=47549117227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47549117227&partnerID=8YFLogxK

M3 - Article

C2 - 18425362

AN - SCOPUS:47549117227

VL - 19

SP - 1085

EP - 1091

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -